Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the Cervix: An EORTC gynaecological cancer cooperative group study

M. E L Van Der Burg, G. Bolis, P. J M Bakker, D. Curran, T. Sahmoud, J. B. Vermorken

Research output: Contribution to journalArticlepeer-review

Abstract

In this study 22 patients with metastatic adenocarcinoma of the cervix were treated with a weekly bolus injection of 4'-epidoxorubicin at a dose of 12 mg/m2. Seventeen patients had received prior radiotherapy, all patients were chemo-naive. Toxicity was generally absent or very mild. One patient had a complete response and 2 patients had a partial response, one was an unconfirmed partial response, giving a response rate of 14%. Six patients had stable disease. The median progression-free survival and overall survival was 2.8 months and 6.1 months, respectively. In conclusion, 4'-epidoxorubicin used at this dosage and schedule has minimal activity in metastatic adenocarcinoma of the cervix.

Original languageEnglish
Pages (from-to)1513-1515
Number of pages3
JournalEuropean Journal of Cancer
Volume33
Issue number9
DOIs
Publication statusPublished - Aug 1997

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the Cervix: An EORTC gynaecological cancer cooperative group study'. Together they form a unique fingerprint.

Cite this